duloxetine has been researched along with dov 216303 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bannwart, LM; Cai, HY; Carter, DS; Choy, JC; Greenhouse, R; Iyer, PS; Jaime-Figueroa, S; Lee, EK; Lin, CJ; Lucas, MC; Lynch, SM; Madera, AM; Moore, A; Ozboya, K; Raptova, L; Roetz, R; Schoenfeld, RC; Stein, KA; Steiner, S; Villa, M; Weikert, RJ; Zhai, Y | 1 |
| Cheon, SH; Choi, K; Hahn, HG; Han, M; Song, C; Yun, J | 1 |
2 other study(ies) available for duloxetine and dov 216303
| Article | Year |
|---|---|
Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.
Topics: Animals; Antidepressive Agents; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Mice; Molecular Structure; Motor Activity; Norepinephrine; Pyrrolidines; Serotonin; Tail | 2008 |
Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.
Topics: Azetidines; Biological Transport; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Neurotransmitter Uptake Inhibitors; Phenyl Ethers; Plasma Membrane Neurotransmitter Transport Proteins; Serotonin; Structure-Activity Relationship | 2014 |